Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
Sarepta Therapeutics, Inc. (SRPT)
Standardized SEC financial data for Sarepta Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000873303 · NASDAQ · Pharmaceutical Preparations.
Income statement
USD
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
$540.1M
$701.9M
$933.0M
$1.24B
$1.79B
$1.86B
Cost of revenue
—
—
—
—
—
$25.5M
Gross profit
—
—
—
—
—
$1.84B
R&D expense
$722.3M
$771.2M
$877.1M
$877.4M
$804.5M
$1.52B
SG&A expense
$317.9M
$282.7M
$451.4M
$481.9M
$557.9M
$491.7M
Operating income
-$564.2M
-$459.7M
-$536.2M
-$267.8M
$218.1M
-$699.8M
EBITDA
-$537.3M
-$421.7M
-$494.3M
-$223.4M
$255.8M
-$655.3M
Interest expense
$59.9M
$63.5M
-$53.2M
-$22.0M
$20.6M
-$38.1M
Pretax income
-$553.1M
-$418.9M
-$690.0M
-$520.1M
$260.8M
-$702.2M
Income tax
$1.1M
$168K
$13.5M
$15.9M
$25.5M
$11.2M
Net income
-$554.1M
-$418.8M
-$703.5M
-$536.0M
$252.2M
-$713.4M
EPS (diluted)
$-7.11
$-5.15
$-8.03
$-5.80
—
—
Standardized from Sarepta Therapeutics, Inc.'s SEC filings — per-share figures split-adjusted. Full history via the API.